Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Gastrointestinal Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 141Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Ramucirumab 33Trastuzumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × fosaprepitant × Gastrointestinal × Clear all
NCT01504711 2021-04-08

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase NA Completed
30 enrolled 12 charts
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡